Canada Markets open in 7 hrs 48 mins

Atossa Therapeutics, Inc. (ATOS)

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
Add to watchlist
1.0400-0.0100 (-0.95%)
At close: 04:00PM EDT
1.0300 -0.01 (-0.96%)
After hours: 07:56PM EDT
Full screen
Trade prices are not sourced from all markets
Previous Close1.0500
Open1.0500
Bid0.0000 x 3200
Ask0.0000 x 1200
Day's Range1.0300 - 1.0600
52 Week Range0.8400 - 4.3100
Volume470,599
Avg. Volume1,350,739
Market Cap131.689M
Beta (5Y Monthly)1.82
PE Ratio (TTM)N/A
EPS (TTM)-0.3100
Earnings DateMar 29, 2022 - Apr 04, 2022
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est5.75
  • GlobeNewswire

    Atossa Therapeutics Appoints Dr. Paul Wabnitz to Its Scientific Advisory Board

    The Company Re-Appoints Drs. Mak Jawadekar, Per Hall, and Carl NovinaSEATTLE, Aug. 18, 2022 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (Nasdaq: ATOS) a clinical stage biopharmaceutical company seeking to develop innovative medicines in areas of significant unmet medical need in oncology and infectious diseases with a current focus on breast cancer and COVID-19, today announces the appointment of Dr. Paul Wabnitz to its Scientific Advisory Board (SAB). The Company has also re-appointed Drs. Ma

  • GlobeNewswire

    Atossa Therapeutics Announces Second Quarter 2022 Financial Results and Provides Corporate Update

    SEATTLE, Aug. 08, 2022 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (Nasdaq: ATOS), a clinical-stage biopharmaceutical company seeking to develop innovative proprietary medicines in oncology and infectious disease with a current focus on breast cancer and COVID-19, today announces financial results for the fiscal quarter ended June 30, 2022, and provides an update on recent company developments. Key developments from Q2 2022 and to date include: Completed dosing in both Part B and Part C (of fo

  • GlobeNewswire

    Dosing Completed in Part C of Atossa’s Phase 1/2a Study of AT-H201 in Healthy Volunteers

    Atossa Plans to Initiate a New Development Path in Patients with Compromised Lung-Function Resulting from Cancer TreatmentSEATTLE, July 28, 2022 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (Nasdaq: ATOS) a clinical stage biopharmaceutical company seeking to develop innovative medicines in areas of significant unmet medical need in oncology and infectious diseases with a current focus on breast cancer and COVID-19, today announces it has completed dosing participants in Part C of its Phase 1/2a